PT - JOURNAL ARTICLE AU - Kamal, Mohamed A. AU - Kuznik, Andreas AU - Qi, Luyuan AU - Więcek, Witold AU - Hussein, Mohamed AU - Hassan, Hazem E. AU - Patel, Kashyap AU - Obadia, Thomas AU - Toroghi, Masood Khaksar AU - Conrado, Daniela J. AU - Al-Huniti, Nidal AU - Casciano, Roman AU - O’Brien, Meagan P. AU - Barnabas, Ruanne V. AU - Cohen, Myron S. AU - Smith, Patrick F. TI - Monoclonal Antibody Treatment, Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread AID - 10.1101/2021.05.21.21257624 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.21.21257624 4099 - http://medrxiv.org/content/early/2021/05/25/2021.05.21.21257624.short 4100 - http://medrxiv.org/content/early/2021/05/25/2021.05.21.21257624.full AB - Background Antiviral monoclonal antibodies (mAbs) developed for treatment of COVID-19 reduce the magnitude and duration of viral shedding and can thus potentially contribute to reducing transmission of the causative virus, severe acute respiratory coronavirus 2 (SARS-CoV-2). However, use of these mAbs in combination with a vaccine program has not been considered in public health strategic planning.Methods We developed an agent-based model to characterize SARS-CoV-2 transmission in the US population during an aggressive phase of the pandemic (October 2020 to April 2021), and simulated the effects on infections and mortality of combining mAbs as treatment and post-exposure prophylaxis (PEP) with a vaccine program plus non-pharmaceutical interventions. We also interrogated the impact of rapid diagnostic testing, increased mAb supply, and vaccine rollout.Findings Allocation of mAbs as PEP or targeting those ≥65 years provided the greatest incremental benefits relative to vaccine in averting infections and deaths, by up to 17% and 41%, respectively. Rapid testing, facilitating earlier diagnosis and mAb use, amplified these benefits. The model was sensitive to mAb supply; doubling supply further reduced infections and mortality, by up to two-fold, relative to vaccine. mAbs continued to provide incremental benefits even as proportion of the vaccinated population increased.Interpretation Use of anti-viral mAbs as treatment and PEP in combination with a vaccination program would substantially reduce SARS-CoV-2 transmission and pandemic burden. These results may help guide resource allocation and patient management decisions for COVID-19 and can also be used to inform public health policy for current and future pandemic preparedness.Funding Regeneron Pharmaceuticals.Competing Interest StatementICMJE disclosure forms provided by the authors are available with the full text of this article.Funding StatementThis study was funded by Regeneron Pharmaceuticals, Inc. Writing support during manuscript development was funded by Regeneron Pharmaceuticals.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research did not require IRB and/or ethics committee approvals.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the supplementary materials.